Evidence map›Paper›PMID 33414971›Full record

ArticleCase reports in hematology2020

Myeloid Disease with the CSF3R T618I Mutation after CLL.

Maria Eduarda Couto, Susana Bizarro, Domingos Sousa, Nelson Domingues, Isabel Oliveira, Gabriela Martins, Manuel R Teixeira, Mário Mariz

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Maria Eduarda CoutoOnco-hematology Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.ORCID https://orcid.org/0000-0003-2092-0325
Susana BizarroGenetics Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.
Domingos SousaInternal Medicine Department, Centro Hospitalar e Universitário Do Algarve E.P.E., Porto, Portugal.
Nelson DominguesOnco-hematology Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.
Isabel OliveiraOnco-hematology Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.
Gabriela MartinsImmunology Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.
Manuel R TeixeiraGenetics Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.ORCID https://orcid.org/0000-0002-4896-5982
Mário MarizOnco-hematology Department, Instituto Português de Oncologia Do Porto F.G. E.P.E., Porto, Portugal.
IPO Porto · PTAlgarve Biomedical Center · PTUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is frequently an indolent diagnosis, with most of the patients being under surveillance for long time. There is an increased risk of a second neoplasia in CLL, rarely hematological (in the myeloid lineage is even rarer). A 58-year-old male was diagnosed with CLL in 2012, remaining in regular surveillance until 2014. Then, the CLL progressed, and 6 cycles of rituximab, fludarabine, and cyclophosphamide were prescribed with partial response. He remained in surveillance and suffered 2 episodes of autoimmune hemolytic anemia until 2019. Then, the hemolytic anemia relapsed and a neutrophilia became evident (progressing slowly), as well as a thrombocytopenia and splenomegaly without adenopathy were found. The bone marrow aspirate showed a chronic myeloproliferative disease without dysplasia. A peripheral blood search for the

Identifiers

PMID33414971
PMCPMC7769667
OpenAlexW3117499188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.